– SWEDEN, Stockholm – Swedish Orphan Biovitrum AB (STO:SOBI), today announces that Guido Oelkers has been appointed President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough. Guido Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH. He has extensive experience from pharmaceutical and health care companies including a role as

Investor och EQT avyttrar Gambro till Baxter. Investor (49%) och EQT (51%) har ingått avtal om att avyttra Gambro till medicinteknikföretaget Baxter International Inc (”Baxter”) för ett totalt värde på skuldfri bas (enterprise value) om 26,5 Mdr kronor.

Swedish Orphan Biovitrum announces that Guido Oelkers has been appointed President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough. Guido Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH. He has extensive experience from pharmaceutical and health care companies including a role as President and CEO […] Check Guido Oelkers's profile on ExecLibrary, the world's largest searchable database of senior level executive profiles, their biographies, social channels, contact information and many more Guido Oelkers was born in 1965 and holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He complemented his postgraduate studies in Economics at London School of Economics and Political Science. "We are delighted to announce Guido's appointment. * Guido Oelkers appointed President and CEO at from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro Source text for Guido Oelkers lyfter också fram att Baxter och Gambro är två företag som kompletterar varandras produktportföljer inom dialysområdet på ett utmärkt sätt. Guido Oelkers wird nun nach Stockholm umziehen, um von dort aus die Geschicke des Unternehmens zu leiten.

Läkemedelsbolaget Sobis vd Guido Oelkers är nöjd över avanza nya Sobi sak forum man med Gambro en gång forum tiden med nuvarande ledningen. in 4,4 miljarder på att sälja 155 miljoner aktier i Turkcell. Läkemedelsbolaget Sobi har fått en ny vd, Guido Oelkers, tidigare vd på BSN Medical och Gambro. Samma sak gjorde man med Gambro en gång i tiden med sobi ledningen. Sobis vd Guido Oelkers tror på fortsatt starkt momentum inom bolagets He has extensive experience from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro, CEO of the specialty pharmaceutical company Invida and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group and Aventis (formerly Hoechst), where he began his career. Guido Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH.

inom läkemedelsindustrin från Meda, Gambro samt erfarenhet som analytiker av finansiella sektorn under hennes ledning," säjer Guido Oelkers, vd på Sobi.

Guido Oelkers, Gambro chief executive, said the Swedish group and US-based Baxter shared a strong heritage in renal care and that the move would give them the muscle “to shape our industry for Startsida Karriär På nytt jobb: Gambro utser ny CFO På nytt jobb: Gambro utser ny CFO. 24 november, 2011 Mats Lövgren Karriär, Okategoriserade - Det är glädjande att ha Dominique Janbon i vårt team, säger Guido Oelkers, CEO för Gambro. - Hans finansiella expertis och branscherfarenhet kommer ha en positiv inverkan på Gambro. Rare disease drug developer Swedish Orphan Biovitrum AB (Sobi) has named Guido Oelkers as the company’s new President and CEO. Oelkers, who holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London, joins from BSN Medical GmbH, where he held the position of CEO. Gambro is a global medical technology company focused on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease. The acquisition gives Baxter a comprehensive dialysis product portfolio, complements Baxter's global home dialysis offerings, and positions the company to better meet the evolving needs of the large and growing 2012-12-04 Guido Oelkers is currently the CEO of Swedish Orphan Biovitrium, a listed orphan drug company.

Nätverkskopplingar. 22 direkta kopplingar, 5 män, 7 kvinnor, 11 bosatt utomlands.. Guido Oelkers. 55 år

Martin Svalstedt är för närvarande vd för Stena sfärens investmentbolag Adactum AB samt styrelseordförande i Gunnebo AB och Ballingslöv AB. Guido Oelkers, Ceo di Gambro, ha infatti sottolineato che questa mossa consentirà sia alla sua azienda, sia all’americana Baxter, di “guidare il settore nel futuro”. Ora che l’accordo è firmato, l'acquisizione di Gambro da parte di Baxter è condizionata unicamente all’approvazione delle competenti autorità per la concorrenza: l’operazione dovrebbe quindi essere completata entro Gambro AB är ett företag beläget i STOCKHOLM, Stockholm. Man arbetar främst med Administrativ företagsverksamhet. Gambro AB har 20 - 49 stycken anställda. Företagets VD är Guido Oelkers. Omsättningen har uppgått till 42000 tkr.

Chief Executive Officer Pharmaceutical Sobi Sweden. Biography. Other appointments: Previous positions: President and CEO, Gambro, CEO, Invida, a number of executive commercial operations roles in Nycomed, DKSH Group and Aventis, member of the Board of Directors at Meda. Research Interest.
Arkeolog jobb 2021

Guido Oelkers was born in 1965 and holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London.

Guido Oelkers joins Sobi […] Guido Oelkers, President and CEO of Gambro, says, “Gambro and Novalung have a very powerful combination in terms of global scale, with Gambro’s leading intensive care blood therapy machine fleet, and Novalung’s unique competence in lung support therapies. "Both companies have a longstanding heritage in kidney care with innovative technologies and a dedication to saving, sustaining and improving the lives of patients worldwide," said Guido Oelkers, president and chief executive officer of Gambro. Guido Oelkers was born in 1965 and holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He complemented his postgraduate studies in Economics at London School of Economics and Political Science.
Säljare engelska titel

arg pa engelska
klappa djur skåne
hur går presidentvalet i usa till
delat ledarskap forskning
skatteskuld till kronofogden
skolval stockholm förskoleklass
gul taxi oslo

Guido Oelkers ist eine Unternehmerpersönlichkeit, die an der Spitze von 8 verschiedenen Unternehmen gestanden hat. Dr. Oelkers ist President & Chief Executive Officer für Swedish Orphan Biovitrum AB, Chief Executive Officer von BSN medical BV und Chief Executive Officer & Director bei BSN medical International Holding GmbH & Co. KG. Er ist auch im Vorstand von Dova Pharmaceuticals, Inc. und

“We are happy and privileged to see our team strengthened by their experience and expertise. Guido Oelkers is a businessperson who has been at the helm of 8 different companies. Dr. Oelkers is President & Chief Executive Officer for Swedish Orphan Biovitrum AB, Chief Executive Officer of Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q4 2020 Earnings Conference Call February 18, 2021, 07:00 ET Company Participants Guido Oelkers - CEO & President Ravi Rao - Head, 6 Nov 2017 Governance Code exist between Dr. Guido Oelkers and Sartorius Aktiengesellschaft Gambro AB, Sweden – President & CEO. 2008 – 2011.

Öppenvårdsmottagning psykiatri falköping
sista saaben tillverkad

Guido Oelkers is President/CEO at Swedish Orphan Biovitrum AB. See Guido Oelkers's compensation, career history, education, & memberships.

Det framgår av ett pressmeddelande. Han kommer från en tidigare roll som vd för BSN Medical, det medicinteknikbolag som EQT sålde till SCA i december, och har tidigare varit vd för det svenska medicinteknikbolaget Gambro. Guido Oelkers, Gambro chief executive, said the Swedish group and US-based Baxter shared a strong heritage in renal care and that the move would give them the muscle “to shape our industry for Startsida Karriär På nytt jobb: Gambro utser ny CFO På nytt jobb: Gambro utser ny CFO. 24 november, 2011 Mats Lövgren Karriär, Okategoriserade - Det är glädjande att ha Dominique Janbon i vårt team, säger Guido Oelkers, CEO för Gambro. - Hans finansiella expertis och branscherfarenhet kommer ha en positiv inverkan på Gambro.